CNS Pharma regains Nasdaq compliance; subject to one-year Mandatory Panel Monitor

CNS Pharmaceuticals, Inc.

On Sep 10, 2024, Nasdaq confirmed CNS Pharma has demonstrated compliance with the $2.5M stockholders' equity requirement; delisting matter closed.
Company is subject to a Mandatory Panel Monitor for one year; if non-compliance recurs, immediate delist with no cure period.
Previous extensions from Aug 2023 to Aug 2024 to regain compliance; now resolved with heightened monitoring.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.